NCT04159974 2024-05-09
RICE
University of Cologne
Phase 2 Unknown
Clinical Trials
58 trialsNCT06255262 2024-02-13
Durvalumab Combined With Surufatinib as Maintenance Therapy in Patients With Advanced Biliary Tract Cancer
China Medical University, China
Phase 1/2 Unknown
NCT05092412 2024-01-12
Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC
Sichuan University
Phase 2 Unknown
NCT04985851 2023-12-01
To Evaluate the Efficacy of Durvalumab + Anlotinib in Terms of OS and PFS.
Shanghai Chest Hospital
Phase NA Unknown
NCT05935579 2023-11-15
Durvalumab and Lenvatinib With or Without Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer
Peking Union Medical College Hospital
Phase 2 Unknown
NCT03446547 2023-11-14
ASTEROID
Vastra Gotaland Region
Phase 2 Unknown
NCT03088059 2023-11-03
UPSTREAM
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Unknown
NCT05451173 2023-10-03
Combining ICI With SBRT or HypoFrx-RT for ES NSCLC
Xuanwu Hospital, Beijing
Phase 1/2 Unknown
NCT04364776 2023-09-28
Radiomic Signature as Predictive Marker of Response to Chemoradiation and Durvalumab in Stage III NSCLC.
Fondazione IRCCS Policlinico San Matteo di Pavia
Unknown
NCT05128630 2023-09-28
DEDALUS
Fondazione IRCCS Policlinico San Matteo di Pavia
Phase 2 Unknown
NCT05382741 2023-05-17
VIVA
Ospedale Policlinico San Martino
Phase 2 Unknown
NCT04202809 2023-05-10
ESPADURVA
University Hospital, Essen
Phase 2 Unknown
NCT03994393 2023-04-21
ILLUMINATE
University of Sydney
Phase 2 Unknown
NCT04646837 2023-03-29
Mechanism of Response to IMFINZI Neoadjuvant Therapy in Non-small Cell Lung Cancer Patients Based on Multiple-omics Models
Peking Union Medical College Hospital
Phase 1/2 Unknown
NCT03975114 2023-03-24
MILES-5
National Cancer Institute, Naples
Phase 2 Unknown
NCT04543110 2023-03-23
RADIANT
Ottawa Hospital Research Institute
Phase 2 Unknown
NCT03737968 2023-03-21
Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.
Yonsei University
Phase 2 Unknown
NCT05429866 2023-03-08
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Jules Bordet Institute
Phase 2 Unknown
NCT04107168 2023-02-16
Microbiome Immunotherapy Toxicity and Response Evaluation
Cambridge University Hospitals NHS Foundation Trust
Unknown
NCT04359199 2023-02-10
QUASAR
University of California, San Diego
Unknown
NCT05312216 2023-01-26
Durvalumab Plus Lenvatinib as First-line Treatment for Unresectable Hepatocellular Carcinoma
Zhejiang University
Phase 2 Unknown
NCT05672537 2023-01-05
Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05640791 2022-12-07
Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT04893252 2022-11-30
Vactosertib and Durvalumab in Gastric Cancer
National Cancer Center, Korea
Phase 2 Unknown
NCT04015739 2022-08-17
BOLD
ARCAGY/ GINECO GROUP
Phase 2 Unknown
NCT03780608 2022-06-15
This Study is a Phase II Study of AZD6738 in Combination With Durvalumab in Patients With Solid Tumor (Cohort A (N=30): GC Who Have Failed Secondary Chemotherapy Treatments Regimen; Cohort B (B=30): Melanoma Patients Who Have Failed to IO)
Samsung Medical Center
Phase 2 Unknown
NCT05327582 2022-04-14
An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTC
Chinese PLA General Hospital
Phase 1/2 Unknown
NCT03799744 2022-03-28
Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma
Institut Català d'Oncologia
Phase 1 Unknown
NCT03759496 2022-03-23
Efficacy of Durvalumab in Non-muscle-invasive Bladder Cancer
Hellenic GenitoUrinary Cancer Group
Phase 2 Unknown
NCT05267392 2022-03-04
IDEAR
Instituto Portugues de Oncologia, Francisco Gentil, Porto
Phase 1/2 Unknown
NCT05245994 2022-02-18
An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese
Sun Yat-sen University
Phase 2 Unknown
NCT05034133 2021-09-05
Durvalumab With Chemotherapy Followed by Sequential Radiotherapy for Limited Stage Small Cell Lung Cancer
Beijing Haidian Hospital
Phase 2 Unknown
NCT05008861 2021-08-17
Gut Microbiota Reconstruction for NSCLC Immunotherapy
Shanghai Zhongshan Hospital
Phase 1 Unknown
NCT03450967 2021-08-10
Durvalumab Plus Tremelimumab Combined With Proton Therapy for HNSCC
Samsung Medical Center
Phase 2 Unknown
NCT04982549 2021-08-06
A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC
Shandong Cancer Hospital and Institute
Phase 2 Unknown
NCT04961918 2021-07-14
The Efficacy of Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Durvalumab (HILL) in Advanced Hepatocellular Carcinoma (HCC)
Sun Yat-sen University
Phase 2 Unknown
NCT04851132 2021-06-22
Radiotherapy Plus Durvalumab in Elderly Esophageal Squamous Cell Carcinoma
ChineseAMS
Phase NA Unknown
NCT04293419 2021-06-21
DUREC
Grupo Espanol Multidisciplinario del Cancer Digestivo
Phase 2 Unknown
NCT04913480 2021-06-04
SBRT and Durvalumab for Inoperable/Unresectable Hepatocellular Carcinoma
The University of Hong Kong
Phase 2 Unknown
NCT04517227 2021-05-03
The Combination Therapy of TACE and Ablation With Durvalumab in Hepatocellular Carcinoma at Intermediate Stage (TAD)
Fudan University
Phase NA Unknown
NCT03699449 2021-04-01
An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION)
Yonsei University
Phase 2 Unknown
NCT03951415 2021-04-01
DOMEC
Leiden University Medical Center
Phase 2 Unknown
NCT03377400 2020-12-17
Definitive CCRT Combined With Durvalumab and Tremelimumab for Inoperable Esophageal Cancer
Samsung Medical Center
Phase 2 Unknown
NCT04672759 2020-12-17
A Real-world Study of Durvalumab for Lung Cancer in China
Peking Union Medical College Hospital
Unknown
NCT04621370 2020-11-09
PRIME-RT
Cancer Research UK, Glasgow
Phase 2 Unknown
NCT04613284 2020-11-03
RELIEF
Shanghai Chest Hospital
Phase 4 Unknown
NCT04443322 2020-09-22
Dulect2020-1
RenJi Hospital
Phase NA Unknown
NCT04447612 2020-06-25
Concurrent Chemoradiation and Durvalumab for Locoregionally Advanced Nasopharyngeal Carcinoma
The University of Hong Kong
Phase 2 Unknown
NCT04444193 2020-06-23
Dulect2020-2
Shanghai First Maternity and Infant Hospital
Phase NA Unknown
NCT03544723 2020-06-09
Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.
MultiVir, Inc.
Phase 2 Unknown